Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28694365 | 0.79 | CHRNB2 (0.36) | CHRNB2CHRNA4CYP19A1MCHR1 | |
| SCHEMBL29499452 | 0.79 | SLC7A5 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL10329129 | 0.76 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL31370973 | 0.72 | CHRNB2 (0.35) | CHRNB2CHRNA4MCHR1 | |
| SCHEMBL12291677 | 0.72 | CHRNB2 (0.35) | CHRNB2CHRNA4MCHR1 | |
| SCHEMBL29994942 | 0.71 | — | — | |
| SCHEMBL15918444 | 0.71 | — | — | |
| SCHEMBL502881 | 0.71 | — | — | |
| SCHEMBL28971358 | 0.71 | TRPV1 (0.32) | CHRNB2CHRNA4 | |
| Ammonia Solution, Strong SCHEMBL27672547 | 0.70 | CA12 (0.43) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20220218679-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218679-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | LTB4R2, LTC4S, CYSLTR1 | CHRNB2 2965/4885CHRNA4 3138/4885CYP19A1 1120/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | CHRNB2 4457/4885CHRNA4 4385/4885CYP19A1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.